Esco
Lifesciences
Group
and
Allwin
Medical
Deal
Signing,
13
February
2025
Strategic
Partnership
Rationale
-
The
IVF
consumables
portfolio
of
Allwin
Medical
will
expand
Esco’s
IVF
instrument
portfolio,
and
the
combined
product
portfolio
will
have
a
complementary
balance
between
consumables
and
instruments.
-
IVF
clinicians
and
embryologists
who
use
either
Allwin’s
consumables
or
Esco’s
time
lapse
or
standard
IVF
incubators
will
have
access
to
a
more
complete
workflow
solution.
-
The
strong
sales
and
operational
presence
of
Allwin
Medical
in
India
will
serve
Esco
well
by
providing
the
company
with
an
established
base
and
strong
presence
in
the
country,
one
of
the
largest
and
fastest
growing
economies
in
the
world.
- Most significantly, the management and personnel of Allwin Medical have demonstrated exceptional talent, acumen, and expertise in the IVF consumables market. Their ongoing contributions to the advancement and success of Allwin Medical is highly valued.
XQ Lin, Chief Executive Officer of Esco, said, “Infertility is a problem that has social, psychological, and economic impacts to the afflicted individuals and couples. It has been estimated that 1 in 6 couples will struggle with infertility at least once in their lifetime. This transaction brings together two companies intent on accelerating innovation for our IVF customers and enabling dreams of couples around the world. Through Esco Medical, our IVF medical devices business unit, Esco Lifesciences Group provides comprehensive ART workflow solutions to IVF clinics, laboratories, and research centers worldwide. Our integrated portfolio, including Time-Lapse Incubators, IVF Workstations, and a witnessing and traceability system designed in Denmark and manufactured in Europe, streamlines processes and optimizes outcomes. With our majority stake, strategic investment in Allwin, we will be in a strong position to fulfill our companies’ missions of enabling our customers to make the world healthier, more equitable, and resilient.”
Dhiren Mehta, Chief Executive Officer and founder of Allwin Medical, noted, “Allwin’s mission since our inception has been to deliver high quality, innovative, and reliable product to laboratories in the IVF/ART and urology markets. We enable our customers to deliver better outcomes to patients globally. By partnering with Esco, we expect to be well-positioned to better serve our customers’ needs worldwide. With Allwin we All Win!”
Dr. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and a member of Esco’s Board of Directors, added, “Novo Holdings has been a strong supporter of Esco since our investment in 2021. The strategic investment in Allwin provides a meaningful growth opportunity for Esco. We are confident that the partnership with the Allwin team and expansion of Esco’s presence in IVF consumables and India will serve both companies well.”
Advisors
Forvis
Mazars
served
as
exclusive
financial
advisor
to
the
Esco
Lifesciences
Group.
IndusLaw
and
Finn
Dixon
&
Herling
LLP
served
as
legal
advisors
to
the
Esco
Lifesciences
Group.
Confluentia
Advisors
served
as
exclusive
financial
advisor
to
Allwin
Medical.
Khaitan
&
Co
and
Bryan
Cave
Leighton
Paisner
LLP
served
as
legal
advisors
to
Allwin
Medical.
https://www.escolifesciences.com
https://www.linkedin.com/company/esco-micro-pte-ltd
https://x.com/EscoLifesci
https://www.facebook.com/escolifesciences/
https://www.instagram.com/escolifesciences/
https://www.esco-medical.com
https://www.group.escolifesciences.com
Hashtag: #EscoLifesciencesGroup #EscoMedical #Esco #AllwinMedical #Allwin #StrategicInvestment #IVF #MedicalDevices #AssistedReproductionTechnlogies
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate